EMA’s human medicines committee (CHMP) recommended 14 medicines for approval at its July 2024 meeting.The CHMP recommended granting a marketing authorisation for Anzupgo (…, Positive recommendations on new medicines , Anzupgo International non-proprietary name (INN) delgocitinib ...

Following a routine review of the safety of the weight loss medicine Mysimba (naltrexone/bupropion), EMA recommends strengthening existing advice to minimise the risks from…

CVMP opinions on veterinary medicinal products The Committee adopted by consensus a positive opinion for a marketing authorisation application for Cepeloron (…

PRAC elects new chairThe July 2024 meeting of EMA’s safety committee (PRAC) was the last plenary meeting chaired by Sabine Straus, who retires as Chair after serving for…, Agenda Agenda of the PRAC meeting 8-11 July 2024DraftReference Number: EMA/PRAC/276333/2024 English (EN…, PRAC statistics: July...

At its July 2024 meeting, EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) elected Ulla Wändel Liminga as its new Chair for a three-year mandate starting in…, Dr Wändel Liminga has been one of the Swedish PRAC delegates since the committee was established in 2012.“As a chair, I want to build on the collective experience of PRAC and…

Georgia Gavriilidou joined EMA on 1 July 2024 as the new Head of the Legal Department, following the retirement of Stefano Marino. She brings over 17 years of in-depth legal and…